Procedure guidelines for MIBG-scintigraphy in children

Summary

The German translation of the EANM guideline for MIBG scintigraphy in children (Olivier P et al. EJNM MI 2003; 30: B45–B50; Hahn K. Der Nuklearmediziner 2002; 25: 101–105) was reviewed and actualized according to current publications, legal requirements and conditions in Germany. For the first time this guideline was generated in consensus with the neuroblastoma study group of the Association of Paediatric Haematologie and Oncology (GPOH) with the result of an interdisciplinary recommendation. Further main alterations are related to the recommended ¹²³I activities with respect to the new EANM Paediatric Dosage Card and the explicit recommendation of SPECT.

Zusammenfassung

Die Leitlinie der EANM zur MIBG-Szintigraphie bei Kindern (Olivier P et al. EJNM MI 2003; 30: B45–B50) in ihrer deutschen übersetzung durch K. Hahn (Der Nuklearmediziner 2002; 25: 101–105) wurde anhand der aktuellen Datenlage sowie der gesetzlichen Rahmenbedingungen und Gegebenheiten in Deutschland überarbeitet und aktualisiert. Erstmals wurde in Deutschland die Empfehlung im Konsens mit der Neuroblastomstudiengruppe der Gesellschaft für Pädiatrische Hämatologie und Onkologie (GPOH) formuliert und damit auf eine interdisziplinäre Ebene gehoben. Weitere wesentliche Neuerungen betreffen die empfohlenen ¹²³I-Aktivitäten unter Berücksichtigung der aktuellen Paediatric Dosage Card der EANM und die ausdrückliche Empfehlung der SPECT.

Keywords

MIBG scintigraphy - neuroblastoma - childhood - guideline

Schlüsselwörter

MIBG-Szintigraphie - Neuroblastom - Kindesalter - Verfahrensanweisung

• Literatur

• 1 Diagnostische Referenzwerte in der Nuklearmedizin. Empfehlungen der Strahlenschutzkommission-Verabschiedet in der 167. Sitzung der Strahlenschutzkommission am 6./7. Juli 2000 2000
• 2 Bonnin F, Lumbroso J, Tenenbaum F. et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994; 35: 803-810.
• 3 Franzius C, Hermann K, Weckesser M. et al. Whole-body PET/CT with C-11-meta-hydroxyephe- drine in tumors of the sympathetic nervous system: feasibility study and comparison with I-123-mIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642.
• 4 Franzius C, Juergens K, Schober O. Is PET/CT necessary in paediatric oncology? For. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
• 5 Franzius C, Lang K, Wormanns D. et al. PET/CT and PET - application in pediatric oncology. Der Nuklearmediziner 2004; 27: 315-323.
• 6 Franzius C, Riemann B, Vormoor J. et al. Metasta- tic neuroblastoma demostrated by whole-body PET-CT using C-11-HED. Nuklearmedizin 2005; 44: N4-N5.
• 7 Gelfand M. I-123-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 2004; 34: 577-579.
• 8 Gelfand M. Meta-iodobenzylguanidine in children. Semin Nucle Med 1993; 23: 231-242.
• 9 Gelfand M, Elgazzar A, Kriss V. et al. Iodine- 123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753-1757.
• 10 Geoerger B, Hero B, Harms D. et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001; 91: 1905-1913.
• 11 Giammarile F, Boneu A, Edeline V. et al. Guide de realisation de la scintigraphie a la meta-iodoben- zylguanidine (mIBG) en oncologie pediatrique. Med Nucl 2000; 24: 35-41.
• 12 Giammarile F, Lumbroso J, Ricard M. et al. Radio- iodinated metaiodobenzylguanidine in neuroblastoma: influence of high-dose on tumour site detection. Eur J Nucl Med 1995; 22: 1180-1183.
• 13 Gordon I, Peters A, Gutman A. et al. Skeletal assessment in neuroblastoma-the pitfalls of iodi-ne-123-MIBG scans. J Nucl Med 1990; 31: 129-134.
• 14 Hahn K, Pfluger T. Is PET/CT necassary in pae- diatric oncology? Against. Eur J Nucl Med Mol Imaging 2006; 33: 966-968.
• 15 Hero B, Berthold F, Engert H. et al. Neuroblastom. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Gesellschaft für Pädiatrische Onkologie und Hämatologie. 2005
• 16 Hickeson M, Charron M, Maris J. et al. Biodistribution of post-therapeutic versus diagnostic I-131-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004; 42: 268-274.
• 17 Hoefnagel C, De Kraker J, Valdes Olmos R. et al. [¹³¹I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39 (Suppl 1) 61-64.
• 18 Hoegerle S, Nitzsche E, Altehoefer C. et al. Pheo- chromocytomas: detection with ¹⁸F-DOPA whole-body PET - initial results. Radiology 2002; 222: 507-512.
• 19 Jacobs A, Delree M, Desprechins B. et al. Consolidating the role of I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol 1990; 20: 157-159.
• 20 Kaarsch P, Spix C. Deutsches Kinderkrebsregister, Jahresbericht 2005. Berlin: Buchdruckerei Johannes Krüger OHG; 2006
• 21 Khafagi F, Shapiro B, Fischer M. et al. Phaeochromo- cytoma and functioning paraganglioma in childhood and adolescence: role ofiodine 131 metaiodobenzylguanidine. Eur J Nucl Med 1991; 18: 191-198.
• 22 Khafagi F, Shapiro B, Gross M. The adrenal gland. In: Maisey M, Britton K, Gilday D. (eds) Clinical Nuclear Medicine. London: Chapman & Hall; 1989: 271-291.
• 23 Kinnier-Wilson L, Draper G. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J 1974; 3: 301-307.
• 24 Knickmeier M, Schäfers M, Schober O. Two years' experience using no-carrier-added meta- [I-123]iodobenzylguanidine in clincal studies. Eur J Nucl Med 2001; 28: 941.
• 25 Kushner B, Cheung N. Exploiting the MIBG-avi- dity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 2006; 47: 863-864.
• 26 Kushner B, Yeh S, Kramer K. et al. Impact of me- taiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086.
• 27 Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004; 45: 1172-1188.
• 28 Kushner BH, Yeung HW, Larson SM. et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18-fluoro- deoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405.
• 29 Lassmann M, Biassoni L, Monieurs M. et al. The New EANM Dosage Card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798.
• 30 Leung A, Shapiro B, Hattner R. et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38: 1352-1357.
• 31 Lumbroso J, Giammarile F, Hartmann O. et al. Upper clavicular and cardiac meta-[¹²³I]iodobenzyl- guanidine uptake in children. Q J Nucl Med 1995; 39: 17-20.
• 32 Lumbroso J, Guermazi F, Hartmann O. et al. Metaiodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988; 271: 689-705.
• 33 Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [¹³¹I]-metaiodo-benzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991; 35: 220-223.
• 34 Mairs R. Neuroblastoma therapy using radiolabeled [¹³¹I]meta-iodobenzylguanidine ([¹³¹I]MIBG) in combination with other agents. Eur J Cancer 1999; 35: 1171-1173.
• 35 Mairs RJ, Cunningham SH, Russell J. et al. No- carrier-added Iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095.
• 36 Moyes J, McCready V, Fullbrook A. Neuroblastoma MIBG in its diagnosis and management. Berlin: Springer; 1989
• 37 Nakajo M, Shapiro B, Copp J. et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682.
• 38 Okuyama C, Ushijima Y, Kubota T. et al. I-123-Metaiodobenzylguanidine uptake in the nape of the neck of children: likly visualization of brown adipose tissue. J Nucl Med 2003; 44: 1421-1425.
• 39 Owens J, Bolster AA, Prosser JE. et al. No-carrier- added I-123-MIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 2000; 21: 437-440.
• 40 Parisi M, Greene M, Dykes T. et al. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992; 27: 768-773.
• 41 Perel Y, Conway J, Kletzel M. et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18.
• 42 Pfluger T, Schmied C, Porn U. et al. Integrated imaging using MRI and I-123-metaiodobenzyl- guanidine scintigraphy to improve sensitivity and specificity in the diagnodid of pediatric neuroblastoma. Am J Roentgenol 2003; 181: 1115-1124.
• 43 Piepsz A, Hahn K, Roca I. et al. A radiopharma- ceutical schedule for image in pediatric. Recommendations of the pediatric task group of the European Association of Nuclear Medicine. Eur J Nucl Med 1990; 17: 127-129.
• 44 Pintelon H, Jonckheer M, Piepsz A. Paediatric nuclear medicine procedures: routine sedation or management of anxiety. Nucl Med Commun 1994; 15: 664-666.
• 45 Rufini V, Fisher G, Shulkin B. et al. Iodine- 123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996; 37: 1464-1468.
• 46 Rufini V, Giordano A, Di Giuda D. et al. [¹²³I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 4: 25-28.
• 47 Schmidt M, Eschner W, Dietlein M. et al. Konventionelle nuklearmedizinische Tumordiagnostik (Tumor-SPECT): Was ist angesichts von F-18-FDG-PET noch aktuell?. Nuklearmedizin 2005; 44: 37-48.
• 48 Schmidt M, Simon T, Hero B. et al. Is there a benefit of I-131-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-151.
• 49 Shapiro B, Copp J, Sisson J. et al. Iodine-131 meta- iodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-585.
• 50 Shulkin B, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39: 679-688.
• 51 Shulkin BL, Hutchinson RJ, Castle VP. et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750.
• 52 Shulkin BL, Koeppe RA, Francis IR. et al. Pheo- chromocytomas that do not accumulate metai- odobenzylguanidine: Localization with PET and administration of FDG. Radiology 1993; 186: 711-715.
• 53 Shulkin BL, Wieland DM, Baro ME. et al. PET Hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996; 37: 16-21.
• 54 Shulkin BL, Wieland DM, Schwaiger M. et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 1992; 33: 1125-1131.
• 55 Sisson J, Shulkin B. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43: 217-223.
• 56 Solanki K, Bomanji J, Moyes J. et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodo- benzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.
• 57 Stabin M, Gelfand M. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42: 93-112.
• 58 Trampal C, Engler H, Juhlin C. et al. Pheochromo- cytomas: Detection with C-11 hydroxyephedrine PET. Radiology 2004; 230: 423-428.
• 59 Wieland D, Wu J, Brown L. et al. Radiolabeled adrenergi neuron-blocking agents: adrenomedul- lary imaging with [¹³¹I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
• 60 Young JJ, Ries L, Silverberg E. et al. Cancer incidence, survival, and mortality for children younger than age 15years. Cancer 1986; 58 (Suppl 2) 598-602.